Literature DB >> 2451570

Suppression of experimental autoimmune encephalomyelitis by the oral administration of myelin basic protein.

D M Bitar1, C C Whitacre.   

Abstract

The oral administration of myelin basic protein (MBP) to Lewis rats prior to an encephalitogenic challenge resulted in total inhibition or a significant delay in the onset of experimental autoimmune encephalomyelitis (EAE). In vitro lymphocyte proliferative responses to MBP were significantly decreased in MBP-fed rats when compared with vehicle-fed controls. Suppression of EAE and in vitro proliferative responses to MBP were observed to be antigen specific, since oral feeding of a control protein exerted no suppressive effect. Moreover, the specificity of MBP-induced oral tolerance was shown to be species specific, since feeding guinea pig MBP (GPMBP) or human MBP (HuMBP) induced protection only against a GPMBP or HuMBP challenge, respectively. Conversely, Lewis rats could not be orally tolerized to the self antigen rat MBP.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2451570     DOI: 10.1016/0008-8749(88)90305-x

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  48 in total

1.  Oral tolerance, an active immunologic process mediated by multiple mechanisms.

Authors:  H L Weiner
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 2.  T-cell based immunotherapy in experimental autoimmune encephalomyelitis and multiple sclerosis.

Authors:  Kate O'Brien; Bruno Gran; Abdolmohamad Rostami
Journal:  Immunotherapy       Date:  2010-01       Impact factor: 4.196

Review 3.  Immune modulating peptides for the treatment and suppression of multiple sclerosis.

Authors:  Ahmed H Badawi; Teruna J Siahaan
Journal:  Clin Immunol       Date:  2012-06-05       Impact factor: 3.969

4.  Treatment of experimental autoimmune encephalomyelitis by feeding myelin basic protein conjugated to cholera toxin B subunit.

Authors:  J B Sun; C Rask; T Olsson; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

5.  Induction of circulating myelin basic protein and proteolipid protein-specific transforming growth factor-beta1-secreting Th3 T cells by oral administration of myelin in multiple sclerosis patients.

Authors:  H Fukaura; S C Kent; M J Pietrusewicz; S J Khoury; H L Weiner; D A Hafler
Journal:  J Clin Invest       Date:  1996-07-01       Impact factor: 14.808

Review 6.  Neuroimmunotherapies Targeting T Cells: From Pathophysiology to Therapeutic Applications.

Authors:  Stefan Bittner; Heinz Wiendl
Journal:  Neurotherapeutics       Date:  2016-01       Impact factor: 7.620

7.  Neonatal induction of myelin-specific Th1/Th17 immunity does not result in experimental autoimmune encephalomyelitis and can protect against the disease in adulthood.

Authors:  Harald H Hofstetter; Andra Kovalovsky; Carey L Shive; Paul V Lehmann; Thomas G Forsthuber
Journal:  J Neuroimmunol       Date:  2007-05-04       Impact factor: 3.478

8.  Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance.

Authors:  J B Sun; J Holmgren; C Czerkinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1994-11-08       Impact factor: 11.205

Review 9.  Oral tolerance in disease.

Authors:  P Garside; A M Mowat; A Khoruts
Journal:  Gut       Date:  1999-01       Impact factor: 23.059

Review 10.  Immune Tolerance for Autoimmune Disease and Cell Transplantation.

Authors:  Xunrong Luo; Stephen D Miller; Lonnie D Shea
Journal:  Annu Rev Biomed Eng       Date:  2016-02-24       Impact factor: 9.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.